Resistance mechanisms to mTOR inhibition in renal cancer
<b>Introduction</b>: Advanced clear cell renal cell cancer (CCRCC) is incurable, but molecularly targeted treatments have improved the prognosis. One such molecular target is the mammalian target of rapamycin (mTOR) and two rapalogues (everolimus and temsirolimus) have been licensed for...
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
University of Oxford
2015
|
| Subjects: | |
| Online Access: | https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.712086 |